Understanding Intended Purpose in EU MDR & IVDR: Key Implications for Medical Device Manufacturers

REPHINE SPEECH MARKS OPEN MEDICALDEVICES

The intended purpose is a fundamental regulatory concept that shapes the classification, safety, and market approval of medical and in vitro diagnostic devices.

REPHINE SPEECH MARKS CLOSE MEDICALDEVICES

About this Guide

This guide provides a comprehensive overview of the “intended purpose” as defined in Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR).

It explores the regulatory definition, its key components, and its critical role in ensuring compliance, patient safety, and successful market entry for medical devices and in vitro diagnostic (IVD) devices in the European Union.

 

Why Is Intended Purpose Important?

The intended purpose is a cornerstone of the MDR and IVDR frameworks, impacting:

  • Device Risk Classification: Determines the level of regulatory scrutiny and conformity assessment procedures.
  • Clinical Evaluation & Performance Evaluation: Defines the scope of clinical investigations and performance studies required to demonstrate safety and efficacy.
  • Post-Market Surveillance (PMS): Guides ongoing monitoring and reporting of adverse events to ensure real-world safety.


Gain a deeper understanding of the intended purpose and its implications for your medical or IVD devices.

Download the guide now to ensure your documentation is audit-ready and fully aligned with EU regulations.

Hero Image Intended Purpose Guide MedTech

Key Topics Covered

  1. Definition of Intended Purpose: Learn how the MDR and IVDR define intended purpose and its importance in regulatory compliance.

  2. Linked Concepts: Explore related terms such as indications for use, target populations, intended users, and use environment.

  3. Intended Purpose as the Cornerstone of Technical Documentation: Understand how intended purpose influences risk classification, clinical evaluation, and post-market surveillance.

  4. Conclusion: Discover why clearly defining and substantiating intended purpose is critical for regulatory success and patient safety.

View our other resources and company news

BANNER Practical Guide to Post Market Surveillance PMS under EU MDR IVDR CSV

Practical Guide to the EMA’s Draft EU GMP Revisions

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
BANNER Practical Guide to Post Market Surveillance PMS under EU MDR IVDR Guide

Practical Guide to Post-Market Surveillance (PMS) under EU MDR/IVDR

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

AI for Pharmaceutical SOPs: Transforming Quality Management and Compliance

Rephine helps pharmaceutical and biotech companies transition to digital QMS platforms like Veeva Vault, MasterControl, or TrackWise. From vendor-neutral selection to full GxP-compliant validation and ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan CAPA

Strengthening CAPA & Exceptions Management

Learn how Rephine’s tailored GxP training helped a pharmaceutical manufacturer strengthen CAPA effectiveness, improve compliance, and boost team confidence.
Read More
GMP Raising the bar Blog series Header image May 25 Blog

EU GMP Annex 1 vs FDA Aseptic Guide: Bridging Compliance

EU and U.S. regulators share the same sterility assurance goals, but their approaches differ. Learn how to align Annex 1 and FDA guidance to streamline ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

GMP & GDP: Ensuring Quality in Drug Storage and Transport

Storage and transport aren’t just logistics — they’re critical GMP processes. Discover how USP helps pharma companies manage risk and maintain quality across global ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

Blockchain for GMP Documentation: Hype or Future Reality?

Blockchain promises immutability, traceability, and transparency for GMP documentation. But is it a compliance game-changer — or just hype?
Read More
Medical Device Guide

Is Your Insurance Policy Ready for the New EU Product Liability Directive?

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
News update: 100% drug tariffs in the USA impacting pharmaceutical supply chains and compliance Article

100% Drug Tariffs in the U.S. – Impact on Pharma Supply Chains & Compliance

The U.S. has announced sweeping 100% tariffs on patented medicines, disrupting pharma supply chains and market access. Discover what this means for manufacturers — and ...
Read More
Contact Us

Strengthen Your Assurance Journey

GMP Chapter 22 Adapting to Hybrid Documentation Standards